- Posted Date: June 30, 2015
- Open Date (Earliest Submission Date): October 25, 2015
- Letter of Intent Due Date(s): 30 days before application due date
- Application Due Date(s): November 25, 2015; May 26, 2016; September 21, 2016; May 26, 2017; September 21, 2017, April 6, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- AIDS Application Due Date(s): Not Applicable
- Scientific Merit Review: March/April 2016; September/October 2016; January/February 2017; September/October 2017; January/February 2018; June/July 2018
- Advisory Council Review: May 2016; October 2016; January 2017; October 2017; May 2018; October 2018
- Earliest Start Date: July 2016; April 2017; July 2017; April 2018; July 2018; December 2018
This Funding Opportunity Announcement (FOA) invites applications from multi-disciplinary teams of researchers and clinicians to establish the Pancreatic Cancer Detection Consortium (PCDC) to conduct research to improve the detection of early stage pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions. This initiative addresses one of the four research priorities identified in the National Cancer Institute's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma. The PCDC is intended to support research for the development and testing of new molecular and imaging biomarkers for identifying patients at high risk for PDAC (because of genetic factors or the presence of precursor lesions) who could be candidates for early intervention. The research will be conducted by individual multi-disciplinary research teams, hereafter called Units. The Units will undertake studies on the following areas: identification and testing of biomarkers measurable in bodily fluids for early detection of PDAC or its precursor lesions; determine which pancreatic cysts are likely to progress to cancer; develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC; conduct biomarker validation studies; and collect longitudinal biospecimens for the establishment of a biorepository. All Units are expected to participate in collaborative activities with other Units and share ideas, specimens and data within the Consortium.